Literature DB >> 1514905

Breast conservation management of breast tumors 4 cm or larger.

M M Khanna1, R J Mark, M J Silverstein, G Juillard, B Lewinsky, A E Giuliano.   

Abstract

Randomized studies of stage I and II breast cancer have shown that breast conservation treatment is equivalent to modified radical mastectomy in regard to local-regional control and survival. Little has been published on breast conservation for patients with large tumors. We analyzed 68 patients with tumors measuring 4 cm or larger (range, 4 to 12 cm) treated with breast-conserving surgery and radiation therapy. The median follow-up was 46 months; the mean tumor size was 5 cm. The 5-year actuarial local-regional recurrence rate was 8.5%, and the overall survival and disease-free survival rates were 76% and 68%, respectively. We conclude that breast conservation treatment may be a reasonable alternative to mastectomy in patients with tumors 4 cm or larger without compromise in local-regional control or survival, while achieving acceptable cosmesis.

Entities:  

Mesh:

Year:  1992        PMID: 1514905     DOI: 10.1001/archsurg.1992.01420090042007

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

Review 1.  Recent developments in breast-conserving surgery for breast cancer patients.

Authors:  F Fitzal; O Riedl; R Jakesz
Journal:  Langenbecks Arch Surg       Date:  2008-09-10       Impact factor: 3.445

2.  Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management.

Authors:  M H El-Didi; M M Moneer; H M Khaled; S Makarem
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

3.  Breast conservation versus mastectomy in patients with T3 breast cancers (> 5 cm): an analysis of 37,268 patients from the National Cancer Database.

Authors:  Anna M Mazor; Alina M Mateo; Lyudmila Demora; Elin R Sigurdson; Elizabeth Handorf; John M Daly; Allison A Aggon; Penny R Anderson; Stephanie E Weiss; Richard J Bleicher
Journal:  Breast Cancer Res Treat       Date:  2018-10-20       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.